CD74

CD74
Identifiers
AliasesCD74, DHLAG, HLADG, II, Ia-GAMMA, CD74 molecule, p33, CLIP
External IDsOMIM: 142790; MGI: 96534; GeneCards: CD74
Available structures
PDBOrtholog search: PDBe RCSB
Orthologs
DatabasesNCBI: entry; OMA: entry
SpeciesHumanMouse
Entrez

972

16149

Ensembl

ENSG00000019582

ENSMUSG00000024610

UniProt

P04233

P04441

RefSeq (mRNA)

NM_004355
NM_001025158
NM_001025159
NM_001364083
NM_001364084

NM_001042605
NM_010545

RefSeq (protein)

NP_001020329
NP_001020330
NP_004346
NP_001351012
NP_001351013

NP_001036070
NP_034675

Location (UCSC)Chr 5: 150.4 – 150.41 MbChr 18: 60.94 – 60.95 Mb
PubMed search
Wikidata
View/Edit HumanView/Edit Mouse

HLA class II histocompatibility antigen gamma chain also known as HLA-DR antigens-associated invariant chain or CD74 (Cluster of Differentiation 74), is a protein that in humans is encoded by the CD74 gene. The invariant chain (Abbreviated Ii) is a polypeptide which plays a critical role in antigen presentation. It is involved in the formation and transport of MHC class II peptide complexes for the generation of CD4+ T cell responses. The cell surface form of the invariant chain is known as CD74. CD74 is a cell surface receptor for the cytokine macrophage migration inhibitory factor (MIF).

Structure

The nascent MHC class II protein in the rough endoplasmic reticulum (RER) binds a segment of the invariant chain (Ii; a trimer), which shapes the peptide-binding groove and prevents the formation of a closed conformation. CD74 exists in several isoforms, most commonly p33, p35, p41, and p43, generated by alternative splicing and translation initiation sites. Isoforms p33/35 and p41/43 differ in the length of their luminal domains, with p41 and p43 containing an additional thyroglobulin-like region that influences proteolytic processing and MHC class II antigen presentation. Isoforms p35 and p43 also contain N-terminal extensions that enhance endoplasmic reticulum retention relative to p33 and p41.

Function

The invariant chain facilitates the export of MHC class II molecules from the RER in transport vesicles. The signal for endosomal targeting resides in the cytoplasmic tail of the invariant chain, directing the complex to late endosomes containing endocytosed antigens from the exogenous pathway. Binding of the invariant chain prevents peptides from the endogenous pathway, which are destined for MHC class I molecules, from occupying the peptide-binding groove of MHC class II molecules.

The invariant chain is subsequently cleaved by cathepsin S (cathepsin L in cortical thymic epithelial cells), leaving only the CLIP fragment bound within the peptide-binding groove of MHC class II molecules, while the remainder of the invariant chain is degraded. CLIP prevents premature peptide binding until HLA-DM catalyzes its release, allowing antigenic peptides to bind. In some cases, CLIP dissociates spontaneously, whereas in others its interaction with MHC class II is sufficiently stable to require HLA-DM-mediated peptide exchange.

The resulting stable MHC class II–antigen complex is then presented on the cell surface for recognition by CD4+ T cells. In the absence of CLIP, MHC class II molecules aggregate, dissociate, or denature within endosomes, impairing efficient antigen presentation.

Clinical significance

Vaccine adjuvant

The Ii molecule—fused with a viral vector to a conserved region of the Hepatitis C virus (HCV) genome—has been tested as an adjuvant for a HCV vaccine in a cohort of 17 healthy human volunteers. This experimental vaccine was well-tolerated, and those who received the adjuvanted vaccine had stronger anti-HCV immune responses (enhanced magnitude, breadth and proliferative capacity of anti-HCV-specific T-cells) compared with volunteers who received the vaccine that lacked the Ii adjuvant.

The Ii molecule might also prove to be useful as an adjuvant for a future vaccine for the SARS-CoV-2 virus, if this enhancing effect can be demonstrated to apply to the appropriate antigen(s).

Cancer

Found on a number of cancer cell types. Possible cancer therapy target. See milatuzumab.

Axial spondyloarthritis

Autoantibodies against CD74 have been identified as promising biomarkers in the early diagnosis of the autoimmune disease called axial spondyloarthritis (non-radiographic axial spondyloarthritis and radiographic axial spondyloarthritis / Ankylosing spondylitis).

Interactions

CD74 receptor interacts with the cytokine Macrophage migration inhibitory factor (MIF) to mediate some of its functions.

Recovery functions

Role of CD74 receptor in tissue injury and wound repair

CD74 receptor is expressed on the surface of different cell types. Interaction between MIF cytokine and its cell membrane receptor CD74 activates pro-survival and proliferative pathways that protect against injury and promote healing in different parts of the body.

History

The invariant chain was first described by Patricia P. Jones, Donal B. Murphy, Derek Hewgill, and Hugh McDevitt at Stanford. The nomenclature "Ii" comes from an Ix-based naming system (I for Immune) that predates the naming of the Major Histocompatibility Complex.

See also

References

  1. 1 2 3 GRCh38: Ensembl release 89: ENSG00000019582 – Ensembl, May 2017
  2. 1 2 3 GRCm38: Ensembl release 89: ENSMUSG00000024610 – Ensembl, May 2017
  3. ↑ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ↑ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ↑ Claesson L, Larhammar D, Rask L, Peterson PA (December 1983). "cDNA clone for the human invariant gamma chain of class II histocompatibility antigens and its implications for the protein structure". Proceedings of the National Academy of Sciences of the United States of America. 80 (24): 7395–7399. Bibcode:1983PNAS...80.7395C. doi:10.1073/pnas.80.24.7395. PMC 389957. PMID 6324166.
  6. ↑ Kudo J, Chao LY, Narni F, Saunders GF (December 1985). "Structure of the human gene encoding the invariant gamma-chain of class II histocompatibility antigens". Nucleic Acids Research. 13 (24): 8827–8841. doi:10.1093/nar/13.24.8827. PMC 318954. PMID 3001652.
  7. ↑ "UniProtKB - P04233 (HG2A_HUMAN)". UniProt. The UniProt Consortium. 2020. Retrieved Aug 10, 2020.
  8. ↑ Cresswell P (1994). "Assembly, transport, and function of MHC class II molecules". Annual Review of Immunology. 12: 259–293. doi:10.1146/annurev.iy.12.040194.001355. PMID 8011283.
  9. 1 2 Farr L, Ghosh S, Moonah S (2020). "Role of MIF Cytokine/CD74 Receptor Pathway in Protecting Against Injury and Promoting Repair". Frontiers in Immunology. 11 1273. doi:10.3389/fimmu.2020.01273. PMC 7325688. PMID 32655566.
  10. ↑ Borghese F, Clanchy FI (2011-03-01). "CD74: an emerging opportunity as a therapeutic target in cancer and autoimmune disease". Expert Opinion on Therapeutic Targets. 15 (3): 237–251. doi:10.1517/14728222.2011.550879. ISSN 1472-8222. PMID 21208136.
  11. 1 2 Owen JA, Punt J, Stranford SA, Jones PP, Kuby J (2013). Kuby immunology (7th ed.). New York: W.H. Freeman. ISBN 978-1-4641-1991-0. OCLC 820117219.
  12. ↑ Schulze MS, Wucherpfennig KW (February 2012). "The mechanism of HLA-DM induced peptide exchange in the MHC class II antigen presentation pathway". Current Opinion in Immunology. 24 (1): 105–111. doi:10.1016/j.coi.2011.11.004. PMC 3288754. PMID 22138314.
  13. ↑ Vogt AB, Kropshofer H (April 1999). "HLA-DM - an endosomal and lysosomal chaperone for the immune system". Trends in Biochemical Sciences. 24 (4): 150–154. doi:10.1016/S0968-0004(99)01364-X. PMID 10322421.
  14. ↑ Esposito I, Cicconi P, D'Alise AM, Brown A, Esposito M, Swadling L, et al. (June 2020). "MHC class II invariant chain-adjuvanted viral vectored vaccines enhances T cell responses in humans". Science Translational Medicine. 12 (548) eaaz7715. doi:10.1126/scitranslmed.aaz7715. PMC 7610808. PMID 32554708. S2CID 219722045.
  15. ↑ Larkin M (June 24, 2020). "Adjuvanted viral-vectored vaccine promising against hepatitis C in early trial". Reuters Health News. GI Health Foundation. Retrieved Aug 10, 2020.
  16. ↑ Baerlecken NT, Nothdorft S, Stummvoll GH, Sieper J, Rudwaleit M, Reuter S, et al. (June 2014). "Autoantibodies against CD74 in spondyloarthritis". Annals of the Rheumatic Diseases. 73 (6): 1211–1214. doi:10.1136/annrheumdis-2012-202208. PMID 23687263. S2CID 22939188.
  17. ↑ Ghosh S, Padalia J, Ngobeni R, Abendroth J, Farr L, Shirley DA, et al. (March 2020). "Targeting Parasite-Produced Macrophage Migration Inhibitory Factor as an Antivirulence Strategy With Antibiotic-Antibody Combination to Reduce Tissue Damage". The Journal of Infectious Diseases. 221 (7): 1185–1193. doi:10.1093/infdis/jiz579. PMC 7325720. PMID 31677380.
  18. ↑ Shan ZX, Lin QX, Deng CY, Tan HH, Kuang SJ, Xiao DZ, et al. (December 2009). "[Identification of the interactions between the truncated fragments of macrophage migration inhibitory factor and CD74 using a yeast two-hybrid system]". Nan Fang Yi Ke da Xue Xue Bao = Journal of Southern Medical University (in Chinese). 29 (12): 2383–6, 2390. PMID 20034881.
  19. ↑ Wang F, Shen X, Guo X, Peng Y, Liu Y, Xu S, et al. (February 2010). "Spinal macrophage migration inhibitory factor contributes to the pathogenesis of inflammatory hyperalgesia in rats". Pain. 148 (2): 275–283. doi:10.1016/j.pain.2009.11.011. PMID 20005040. S2CID 38141283.
  20. ↑ Dobson SE, Augustijn KD, Brannigan JA, Schnick C, Janse CJ, Dodson EJ, et al. (December 2009). "The crystal structures of macrophage migration inhibitory factor from Plasmodium falciparum and Plasmodium berghei". Protein Science. 18 (12): 2578–2591. doi:10.1002/pro.263. PMC 2798171. PMID 19827093.
  21. ↑ Piette C, Deprez M, Roger T, Noël A, Foidart JM, Munaut C (November 2009). "The dexamethasone-induced inhibition of proliferation, migration, and invasion in glioma cell lines is antagonized by macrophage migration inhibitory factor (MIF) and can be enhanced by specific MIF inhibitors". The Journal of Biological Chemistry. 284 (47): 32483–32492. doi:10.1074/jbc.M109.014589. PMC 2781663. PMID 19759012.
  22. ↑ Verjans E, Noetzel E, Bektas N, Schütz AK, Lue H, Lennartz B, et al. (July 2009). "Dual role of macrophage migration inhibitory factor (MIF) in human breast cancer". BMC Cancer. 9 230. doi:10.1186/1471-2407-9-230. PMC 2716369. PMID 19602265.
  23. ↑ Jones PP, Murphy DB, Hewgill D, McDevitt HO (January 1979). "Detection of a common polypeptide chain in I--A and I--E sub-region immunoprecipitates". Molecular Immunology. 16 (1): 51–60. doi:10.1016/0161-5890(79)90027-0. PMID 376435.

Further reading